Cem Yesiloglu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Cem Yesiloglu has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Canan Emiroğlu
SAĞLIK BİLİMLERİ ÜNİVERSİTESİ, ANKARA DIŞKAPI YILDIRIM BEYAZIT SAĞLIK UYGULAMA VE ARAŞTIRMA MERKEZİ
2 shared publications - Cenk Aypak
University of Health Sciences, Department of Family Medicine, Ankara Etlik City Hospital
2 shared publications - Murat Dicle
Department of Family Medicine, University of Health Sciences Dışkapı Training and Research Hospital
1 shared publication - Süleyman Görpelioğlu
Department of Family Medicine, University of Health Sciences Dışkapı Training and Research Hospital
1 shared publication
Latest Publications
- 7 March 2024
- Published by Springer Nature in International Journal of Diabetes in Developing Countries
- Vol. 45 (1) , 33-39
The relationship between glycated hemoglobin (HbA1c), hematocrit, mean platelet volume, total white blood cell counts, Visceral Adiposity Index, and Systematic Coronary Risk Evaluation 2 (SCORE2) in patients without diabetes
- 7 March 2024
- Published by Springer Nature in International Journal of Diabetes in Developing Countries
- Vol. 45 (1) , 33-39
The relationship between glycated hemoglobin (HbA1c), hematocrit, mean platelet volume, total white blood cell counts, Visceral Adiposity Index, and Systematic Coronary Risk Evaluation 2 (SCORE2) in patients without diabetes
- 25 November 2023
- Published by Springer Nature in Endocrine
- Vol. 84 (2) , 470-480
Association between newly diagnosed hyperglycemia/diabetes mellitus, atherogenic index of plasma and obesity in post-COVID-19 syndrome patients
Purpose The COVID-19 pandemic represents a great global concern and its associated morbidities. The goal of this study was to determine the incidence of newly diagnosed hyperglycemia and diabetes among COVID-19 survivors and to evaluate whether obesity and lipid profile have an effect on this group using the atherogenic index of plasma (AIP). Methods In the retrospective study, 511 adults with a previously diagnosed “Severe Acute Respiratory Syndrome Coronavirus 2” who admitted to COVID-19 follow-up outpatient clinic were evaluated. Data was collected on patient demographics, comorbidities, and some laboratory results. Logistic regression was used to estimate associated factors. Results Newly diagnosed type 2 diabetes mellitus (T2DM) was defined in 17 patients (3.32%), hyperglycemia in 86 patients (16.82%). The results of analysis were examined, gender, age, BMI and triglyceride variables were found to be significant risk factors together. Fasting blood glucose values of 22 out of 86 patients with hyperglycemia returned to normal after six months of follow-up. Undiagnosed-preexisting DM in 4 out of 17 patients diagnosed with T2DM at their first visit and in 7 out of 8 hyperglycemia patients diagnosed with T2DM at the end of six-month follow-up. Conclusion COVID-19, may directly/indirectly, predispose to hyperglycemia. Obesity and hyperlipidemia are risk factors for newly diagnosed T2DM/hyperglycemia in post-COVID-19 syndrome patients. Since that some metabolic variables were found to be significantly higher in the group with high AIP values, we suggest that AIP might be used as a reference to predict the development of obesity and T2DM.
- 25 November 2023
- Published by Springer Nature in Endocrine
- Vol. 84 (2) , 470-480
Association between newly diagnosed hyperglycemia/diabetes mellitus, atherogenic index of plasma and obesity in post-COVID-19 syndrome patients
Purpose The COVID-19 pandemic represents a great global concern and its associated morbidities. The goal of this study was to determine the incidence of newly diagnosed hyperglycemia and diabetes among COVID-19 survivors and to evaluate whether obesity and lipid profile have an effect on this group using the atherogenic index of plasma (AIP). Methods In the retrospective study, 511 adults with a previously diagnosed “Severe Acute Respiratory Syndrome Coronavirus 2” who admitted to COVID-19 follow-up outpatient clinic were evaluated. Data was collected on patient demographics, comorbidities, and some laboratory results. Logistic regression was used to estimate associated factors. Results Newly diagnosed type 2 diabetes mellitus (T2DM) was defined in 17 patients (3.32%), hyperglycemia in 86 patients (16.82%). The results of analysis were examined, gender, age, BMI and triglyceride variables were found to be significant risk factors together. Fasting blood glucose values of 22 out of 86 patients with hyperglycemia returned to normal after six months of follow-up. Undiagnosed-preexisting DM in 4 out of 17 patients diagnosed with T2DM at their first visit and in 7 out of 8 hyperglycemia patients diagnosed with T2DM at the end of six-month follow-up. Conclusion COVID-19, may directly/indirectly, predispose to hyperglycemia. Obesity and hyperlipidemia are risk factors for newly diagnosed T2DM/hyperglycemia in post-COVID-19 syndrome patients. Since that some metabolic variables were found to be significantly higher in the group with high AIP values, we suggest that AIP might be used as a reference to predict the development of obesity and T2DM.